Treats osteoporosis in postmenopausal women. ANDA 90853, held by Sun Pharmaceutical Industries. Ibandronate Sodium.
As of Nov 21, 2026, ANDA 90853 (Ibandronate Sodium), held by Sun Pharmaceutical Industries, was first approved by FDA on Feb 14, 2014, with 3 approved supplements and 0 published complete response letters.
Ibandronate sodium injection is a bisphosphonate indicated for the treatment of osteoporosis in postmenopausal women. Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use 1.1 Treatment of Postmenopausal Osteoporosis
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 14, 2014 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ibandronate SodiumEQ 3MG BASE/3ML · injectable;intravenous | Ibandronate Sodium | Discontinued |
| Feb 3, 2026 | Supplement 14Labeling · Standard review | Approved | None posted |
| Feb 3, 2026 | Supplement 15Labeling · Standard review | Approved | None posted |
| Sep 2, 2015 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 14, 2014 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters